Veraxa Biotech is trading 9.22% up in pre-market at $1.04, with no new company-specific announcement identified for November 6. - The stock closed at $0.95 on November 5. - The company’s latest listed releases were in October. - Reports describe a Friday biotech rally amid attention on cancer-vaccine developments, but do not link it specifically to Veraxa Biotech; the supplied market context does not establish a direct broader-market catalyst.